Long-Term Durability of Crohn’s Disease Treatment with Infliximab
- 13 October 2007
- journal article
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 53 (4), 1033-1041
- https://doi.org/10.1007/s10620-007-9969-z
Abstract
Background There is a paucity of data providing insight into the durability of Crohn’s disease treatment with infliximab for periods longer than 12 months. Our aim was to assess the long-term durability of infliximab therapy. Materials and Methods A total of 198 Crohn's patients under a maintenance regimen with infliximab, with at least a 30-month follow-up, were evaluated retrospectively. Long-term response maintenance was estimated using Kaplan-Meier analysis. The effect of specific variables was calculated using logistic regression and proportional hazard regression analyses. Results Maintenance of response rates at 72 months was estimated to be 66.4% for initial responders and 58.2% for all patients treated. Concurrent immunomodulators enhanced response maintenance in all patients treated, particularly if started >3 months before the initiation of infliximab therapy. Smoking significantly decreased the maintenance of response in initial responders. Conclusions Infliximab treatment of Crohn’s disease is reasonably durable beyond 12 months. Concurrent immunosuppressive therapy may increase – and smoking may decrease – long-term response maintenance.Keywords
This publication has 36 references indexed in Scilit:
- American Gastroenterological Association Institute Technical Review on Corticosteroids, Immunomodulators, and Infliximab in Inflammatory Bowel DiseaseGastroenterology, 2006
- Are there predictors of Remicade treatment success or failure?Advanced Drug Delivery Reviews, 2005
- Austrian infliximab experience in Crohn's diseaseEuropean Journal of Gastroenterology & Hepatology, 2004
- Infliximab Maintenance Therapy for Fistulizing Crohn's DiseaseNew England Journal of Medicine, 2004
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialThe Lancet, 2002
- Early Australian experience with infliximab, a chimeric antibody against tumour necrosis factor‐α, in the treatment of Crohn’s disease: is its efficacy augmented by steroid‐sparing immunosuppressive therapy?Internal Medicine Journal, 2001
- Infliximab for the Treatment of Fistulas in Patients with Crohn's DiseaseNew England Journal of Medicine, 1999
- Effect of cigarette smoking on the course of Grohnʼs diseaseEuropean Journal of Gastroenterology & Hepatology, 1996
- Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)Gastroenterology, 1995
- Treatment of Crohn's Disease with 6-MercaptopurineNew England Journal of Medicine, 1980